Key Takeaways
- Record revenue and EBITDA, margin diluted by raw materials: FY22 revenue rose 49% YoY and EBITDA hit an all-time high of ₹2,804 crores, but EBITDA margin contracted to 17.24% from 20.5% as raw material price spikes outpaced pass-through mechanisms.
- Aseptic packaging is the breakout story: Capacity utilization jumped from 55% to 86%, the expanded facility is ramping, and the order book is overwhelming in peak season, positioning the segment for strong FY23.
- Russia is a net positive, not a risk: Local sourcing has replaced imports, domestic demand is robust after competitors exited, and the business can be ring-fenced for the Dubai listing if needed. [14-15]
- Management is deliberately leveraged and unapologetic: Net debt to EBITDA sits at 1.74x and the Group CFO stated flatly that becoming net-debt zero is "the most inefficient way to grow." Debt will reduce gradually through amortization, not aggressive paydown.
- What to watch next quarter: Whether the 7-day order book policy in films protects margins if raw materials stay elevated, Nigeria's supply chain fix materializes, and the Flex Middle East listing readiness translates into an actual filing.
Aseptic Packaging: The Growth Engine
- Utilization transformed: Capacity utilization reached 86% in FY22, up from 55% the prior year, driven by the recently commissioned extension and strong demand.
- Demand outstrips supply: The order book is "overwhelming" on a month-to-month basis, and the company cannot keep pace with requirements during the busy summer beverage season.
- Growth trajectory: The segment is growing at an 18-20% annual rate, setting the pace for further expansion, with good numbers expected in FY23.
- Revenue split: Both domestic and export markets are driving growth, with the split running approximately 70% domestic and 30% exports.
- Paper straw compliance underway: Infrastructure is being set up at the Sanand plant ahead of the government's 1st July 2022 ban on plastic straws; more machines will be added over the next six months to achieve full compliance, and the company is prepared for any deadline extension.
- Demerger on the table: Management will discuss internally whether to separately list the aseptic packaging business if high utilization sustains for a couple of years, calling the analyst's suggestion a "great idea."
Rajesh Bhatia: "You are right. Great idea. I think we can, we will definitely discuss internally, if there is a merit in this and there's a value to be taken, why not?"
Raw Material Margin Mechanics
- Films: policy shift to 7-day order book: After supply chain disruptions hurt margins in Q2, the packaging films business moved from a longer order book to a 7-day window, enabling faster pass-through of raw material price changes. This policy will continue.
- Packaging business: a 1-to-3-month lag persists: In the packaging segment, raw material price pass-through still carries a lag of one month to a maximum of three months, which compresses margins when input prices rise. Management admitted the lag openly.
- Markets are absorbing increases: All raw material margin increases are being passed on to customers as quickly as possible, with management describing markets as "very robust."
- Backward integration as structural hedge: The newly announced polyester chip facility for Noida and Dharwad is designed to protect margins and ensure raw material security, with a conservative project IRR of close to 19%.
Rajesh Bhatia: "In the packaging though, still there is a lag there from a months or going maximum up to three months basis. So that lag is going to affect your margins as the raw material prices go up. ... I have no qualms about not admitting that."
Geopolitical Exposure: Russia and Eastern Europe
- Russia is a net positive: The geopolitical situation has only helped the Russia business. Raw materials previously exported to Europe are now available locally, enabling near-100% local sourcing versus earlier dependence on China and other sources. Imports of flexible packaging into Russia have stopped, so local demand is robust. [14-15]
- Eastern Europe unaffected: Operations in Hungary and Poland are "absolutely unaffected" by the war. Some raw materials previously sourced from Russia for Hungary have been reoriented to other destinations, a process already completed.
- Listing ring-fence available: If regulators require Russia to be separated from the mainstream entity for the Flex Middle East listing, the company can do that; the decision will be made closer to the event.
Rajesh Bhatia: "There have been only a positive impact on the Russia business, per say."
Capital Allocation and Leverage
- Deliberate leverage stance: Net debt rose ~₹600 crores versus March 2021 to reach 1.74x net debt to EBITDA, driven by investment in the Dharwad and Dubai facilities. Management explicitly rejects the idea of becoming net-debt zero, calling it "the most inefficient way to grow your business."
- Debt reduction path is organic: With no major capex in sight beyond the ₹580 crores already planned, debt will reduce gradually as amortization of ~₹500 crores per year kicks in. From ~₹4,000 crores net debt currently, the trajectory points to roughly ₹3,000 crores.
- Rating upgrade delivering lower cost: CRISIL upgraded the short-term rating to A1+ and long-term to AA minus; some banks have already reduced interest rates, with others in process.
- FZE listing: dual purpose: The planned Dubai listing of the holding company aims to improve leverage and ratings while providing capital for further growth. Management also expects it to re-value UFlex India, citing materially different valuations in US and European markets. Readiness for filing is expected in the current quarter, with actual listing dependent on regulators and market timing.
- Shareholder suggestions noted, not committed: Management will take back suggestions on a bonus issue from reserves, higher dividend payout of 10-20% of EPS, and separate listing of the aseptic packaging business for internal discussion, without any commitments.
Rajesh Bhatia: "We don't want to become net debts zero company. I think that's the most inefficient way to grow your business."
Demand Resilience and Customer Dynamics
- Recession-proof core: Management does not see demand-side impact from a potential US or Europe recession because 95% of the business is primary food packaging, a basic necessity. Even crude oil at \$130-140/barrel is not expected to dent demand.
- Customer additions slowed by choice, not weakness: Customer additions in flexible packaging declined over the last three years because existing capacities were fully sold out. The company chose not to add smaller customers by sacrificing margins or offering inaugural incentives. Aseptic packaging customer additions, by contrast, increased with enhanced capacity.
- BOPET capacity outlook benign: The number of new BOPET lines coming up in Europe, the US, and other major markets is "quite manageable" and will not disturb the demand-supply equilibrium. No irrational capacity is visible.
- No move into food service packaging: The company has no plans to enter food service packaging, preferring to stay close to aseptic packaging, flexible packaging, and packaging films.
Rajesh Bhatia: "95% of my business is packaging foods, which is the basic necessity for life. So, you know, given that the food and you know, we don't do any fancy food stuffs and all that, we are just the primary packing of the food is our core business. So there, you know, frankly, we don't see any impacts of you know, recession coming and affecting us"
Regulatory and Sustainability Positioning
- EPR rules create opportunity: The new Plastic Waste Management Amendment Rules effective 1st April 2022 impose step-up obligations on brands to recycle plastics or make packaging biodegradable. UFlex does not plan to invest in recycling facilities as a business focus but may help brands with technology and hand-holding.
- Bio-degradable packaging as growth vector: Management sees huge potential in bio-degradable packaging, expecting brands may prefer it over recycling on a cost-benefit basis. UFlex will look to increase revenue from bio-degradable enzymes and flexible packaging.
- Hybrid models expected: The EPR framework is expected to evolve over the next two years as brands decide between recycling and bio-degradable pathways, potentially adopting hybrid models.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Nigeria recovery | Supply chain bottlenecks sorted, better numbers expected | Next 1-2 quarters |
| Aseptic packaging growth | Good numbers expected given 86% utilization and expanded facility ramping | FY23 |
| Dharwad and Dubai contribution | Additional revenues and profitability as facilities commission | FY22 (commissioning) |
| Flex Middle East listing readiness | Absolute readiness for filing expected | Current quarter (Q1 FY23) |
| Paper straw compliance | More machines being added; prepared for any deadline extension | Next six months (partial by 1st July 2022) |
| Debt trajectory | From ~₹4,000 crores net debt to ~₹3,000 crores via amortization and limited new capex | Over next two years |
| PET chips project return | Conservative IRR of close to 19% | Project lifetime |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | Almost ₹4,000 cr, quarterly record |
| FY22 revenue | ₹13,225 cr, up ~49% YoY |
| FY22 volume growth | ~30% in both packaging film and packaging business |
| Q4 EBITDA | ₹734 cr, quarterly highest ever |
| FY22 EBITDA | ₹2,804 cr, up ~25% YoY, highest ever |
| FY22 EBITDA margin | 17.24%, vs 20.5% last year; ~20% when neutralizing raw material impact per management |
| FY22 PAT | ₹1,098 cr, up 30% YoY |
| Egypt currency devaluation impact | ₹38 cr exceptional item, from 16% devaluation of Egyptian pound on 21st March |
| Net debt | ₹3,974 cr, up ~₹600 cr vs March 21 |
| Net debt to EBITDA | 1.74x |
| Long-term debt | ~₹3,500 cr |
| Short-term debt | ~₹1,000 cr |
| Cash on balance sheet | ~₹600 cr |
| Dividend | Up ~30% for the year |
| Dividend payout ratio | 2% in March 2022, declined from 9% in FY14 (per an analyst's math) |
| Aseptic packaging capacity utilization | 86% in FY22, vs 55% last year |
| Aseptic packaging annual growth rate | 18–20% |
| Asepto capacity | 700 cr packs |
| Asepto capacity utilization (recent) | 90% reached |
| Asepto margin guidance | 18–22% |
| Packaging films share of top line | 60–65% |
| International business share | 60–65% |
| ROCE | 16% |
| Borrowing cost (euros/dollars) | 1–2% spreads |
| Next year amortization | ~₹500 cr |
| New capex announced | ~₹580 cr |
| PET chips project IRR | ~19% |